PsiOxus Therapeutics Limited Launches Phase I/II Clinical Trial of Oncolytic Vaccine With Dosing of Patient With Metastatic Cancer

Published: Sep 26, 2012

OXFORD, England--(BUSINESS WIRE)--PsiOxus Therapeutics, Ltd. (PsiOxus) has treated the first patient in its phase I/II clinical trial of ColoAd1 for the treatment of metastatic solid tumours. The Evolve (EValuating OncoLytic Vaccine Efficacy) study is the first clinical trial of the systemically available oncolytic vaccine ColoAd1, a highly potent, broad-spectrum, anti-cancer therapeutic capable of destroying tumour cells at minute concentrations.

Back to news